News & Analysis on the Clinical Development and Manufacture of Large Molecule Drugs
Australia’s Noxopharm has in-licensed novel RNA tech developed by Hudson Institute of Medical Research: focusing on RNA drug discovery and mRNA vaccine manufacture via Noxopharm’s subsidiary Pharmorage.
The European Medicines Agency (EMA) has started a rolling review of VLA2001, Valneva’s COVID-19 vaccine candidate, with the company set to supply up to 60 million doses to the European Union.
Genezen, a cell and gene therapy focused CDMO, has just opened a new process development and analytical lab, a build that represents the first phase of a 75,000+ square foot cGMP-compliant lentiviral and retroviral vector production facility in Indianapolis.